Accelerated cellular senescence in solid tumor therapy

Experimental Oncology

Volumn 34, Issue 3, 2012, Pages 298-305

  Wu, P C ^a,b   Wang, Q ^a   Grobman, L ^a,b   Chu, E ^a   Wu, D Y ^a,b,c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cell cycle arrest; Cellular senescence; Chemotherapeutic agents; Senescence based therapy; Tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PACLITAXEL; PRAVASTATIN; PROTEIN P16; PROTEIN P21; PROTEIN P27; SURVIVIN;

ACCELERATED CELLULAR SENESCENCE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; OVARY CANCER; REVIEW; SENESCENCE; SOLID TUMOR; TREATMENT RESPONSE;

APOPTOSIS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TELOMERE;

EID: 84872479990     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
2. Campisi J. Cancer, aging and cellular senescence. In Vivo 2000; 14: 183-8.
3. Chang BD, Broude EV, Dokmanovic M, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59: 3761-7.
4. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-7.
5. Mooi WJ, Peeper DS. Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med 2006; 355: 1037-46.
6. Castedo M, Perfettini JL, Roumier T, et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23: 2825-37.
7. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005; 4: 139-63.
8. Roberson RS, Kussick SJ, Vallieres E, et al. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005; 65: 2795-803.
9. Ha L, Merlino G, Sviderskaya EV. Melanomage nesis: overcoming the barrier of melanocyte senescence. Cell Cycle 2008; 7: 1944-8.
10. Michaloglou C, Vredeveld LC, Soengas MS, et al . BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-4.
11. Courtois-Cox S, Genther Williams SM, Reczek EE, et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 10: 459-72.
12. Going JJ, Stuart RC, Downie M, et al. "Senescence-associated" beta-galactosidase activity in the upper gastrointestinal tract. J Pathol 2002; 196: 394-400.
13. Larsson LG. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011; 21: 367-76.
14. Saab R. Senescence and pre-malignancy: how do tumors progress? Semin Cancer Biol 2011; 21: 385-91.
15. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434-44.
16. Thames HD, Petersen C, Petersen S, et al. Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther Onkol 2002; 178: 411-21.
17. Zhu Z, Jia J, Lu R, et al. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV). Int J Cancer 2006; 118: 1539-44.
18. Al-Ejeh F, Kumar R, Wiegmans A, et al. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 2010; 29: 6085-98.
19. Ashwell S, Zabludoff S. DNA damage detection and repair pathways - recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin Cancer Res 2008; 14: 4032-7.
20. Harper JW, Elledge SJ. The DNA damage re sponse: ten years after. Mol Cell 2007; 28: 739-45.
21. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet 2006; 7: 45-54.
22. Elmore LW, Di X, Dumur C, et al. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 2005; 11: 2637-43.
23. Portugal J, Bataller M, Mansilla S. Cell death pathways in response to antitumor therapy. Tumori 2009; 95: 409-21.
24. Puig PE, Guilly MN, Bouchot A, et al. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 2008; 32: 1031-43.
25. Walworth NC. DNA damage: Chk1 and Cdc25, more than meets the eye. Curr Opin Genet Dev 2001; 11: 78-82.
26. Featherstone C, Russell P. Fission yeast p107wee1 mitotic inhibitor is a tyrosine/serine kinase. Nature 1991; 349: 808-11.
27. Mueller PR, Coleman TR, Kumagai A, Dun phy WG. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995; 270: 86-90.
28. Richter KH, Afshari CA, Annab LA, et al. Down-regulation of cdc2 in senescent human and hamster cells. Cancer Res 1991; 51: 6010-3.
29. Jee HJ, Kim HJ, Kim AJ, et al. Nek6 suppresses the premature senescence of human cancer cells induced by camptothecin and doxorubicin treatment. Biochem Biophys Res Commun 2011; 408: 669-73.
30. Wada T, Joza N, Cheng HY, et al. MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat Cell Biol 2004; 6: 215-26.
31. Chang BD, Swift ME, Shen M, et al. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci USA 2002; 99: 389-94.
32. Di X, Shiu RP, Newsham IF, Gewirtz DA. Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to adriamycin. Biochem Pharmacol 2009; 77: 1139-50.
33. Shi L, Nishioka WK, Th'ng J, et al. Premature p34cdc2 activation required for apoptosis. Science 1994; 263: 1143-5.
34. Luo P, Tresini M, Cristofalo V, et al. Immortalization in a normal foreskin fibroblast culture following transduction of cyclin A2 or cdk1 genes in retroviral vectors. Exp Cell Res 2004; 294: 406-19.
35. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-9.
36. Li F. Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29.
37. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59: 3143-51.
38. Uren AG, Wong L, Pakusch M, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol 2000; 10: 1319-28.
39. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97: 13103-7.
40. Wall NR, O'Connor DS, Plescia J, et al. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230-5.
41. Wang Q, Wu PC, Roberson RS, et al. Survivin and escaping in therapy-induced cellular senescence. Int J Cancer 2011; 128: 1546-58.
42. Ballot C, Jendoubi M, Kluza J, et al. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II. Apoptosis 2012; 17: 364-76.
43. La Porta CA, Zapperi S, Sethna JP. Senescent cells in growing tumors: population dynamics and cancer stem cells. PLoS Comput Biol 2012; 8: e1002316.
44. Monzo M, Rosell R, Felip E, et al . A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-4.
45. Gianani R, Jarboe E, Orlicky D, et al . Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001; 32: 119-25.
46. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100: 751-7.
47. Das A, Tan WL, Smith DR. Expression of the inhibitor of apoptosis protein survivin in benign meningiomas. Cancer Lett 2003; 193: 217-23.
48. Pizem J, Cor A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 2004; 45: 180-6.
49. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005; 114: 509-12.
50. Ikehara M, Oshita F, Kameda Y, et al. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 2002; 9: 835-8.
51. Zaffaroni N, Pennati M, Colella G, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-12.
52. Gorospe M, Wang X, Holbrook NJ. Functional role of p21 during the cellular response to stress. Gene Expr 1999; 7: 377-85.
53. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-67.
54. Suzuki A, Tsutomi Y, Miura M, Akahane K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 1999; 18: 1239-44.
55. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
56. Shim J, Lee H, Park J, et al. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996; 381: 804-6.
57. Suzuki A, Tsutomi Y, Akahane K, et al . Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998; 17: 931-9.
58. Levkau B, Koyama H, Raines EW, et al . Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998; 1: 553-63.
59. Ullah Z, Lee C, DePamphilis M. Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy. Cell Div 2009; 4: 10.
60. Mirzayans R, Andrais B, Scott A, et al. Single-cell analysis of p16(INK4a) and p21(WAF1) expression suggests distinct mechanisms of senescence in normal human and Li-Fraumeni Syndrome fibroblasts. J Cell Physiol 2010; 223: 57-67.
61. te Poele RH, Okorokov AL, Jardine L, et al . DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62: 1876-83.
62. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-46.
63. Wu PC, Wang Q, Dong D, et al. Expression of coxsackie and adenovirus receptor distinguishes transitional cancer states in therapy-induced cellular senescence. Cell Death Dis 2010; 1: e70.
64. Sidi R, Pasello G, Opitz I, et al. Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: An exploratory analysis. Eur J Cancer 2011; 47: 326-32.
65. Communal C, Huq F, Lebeche D, et al . Decreased efficiency of adenovirus-mediated gene transfer in aging cardiomyocytes. Circulation 2003; 107: 1170-5.
66. Hung SC, Lu CY, Shyue SK, et al. Lineage differentiation-associated loss of adenoviral susceptibility and Coxsackie-adenovirus receptor expression in human mesenchymal stem cells. Stem Cells 2004; 22: 1321-9.
67. Hemmi S, Geertsen R, Mezzacasa A, et al. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363-73.
68. Kim M, Sumerel LA, Belousova N, et al. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br J Cancer 2003; 88: 1411-6.
69. Pearson AS, Koch PE, Atkinson N, et al. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin Cancer Res 1999; 5: 4208-13.
70. Gupta S, Hastak K, Ahmad N, et al. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 2001; 98: 10350-5.
71. Kurz DJ, Decary S, Hong Y, Erusalimsky JD. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 2000; 113: 3613-22.
72. Matuschek C, Rudoy M, Peiper M, et al. Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res 2011; 16: 451-6.
73. Funayama R, Ishikawa F. Cellular senescence and chromatin structure. Chromosoma 2007; 116: 431-40.
74. Haugstetter AM, Loddenkemper C, Lenze D, et al. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer 2010; 103: 505-9.
75. Zhang R, Adams PD. Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 2007; 6: 784-9.
76. Bunn PA, Jr. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 2002; 20: 23S-33S.
77. Senderowicz AM. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 2003; 52 (Suppl 1): S61-73.
78. Wang LM, Ren DM. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem 2010; 10: 1058-70.
79. Graaf MR, Richel DJ, van Noorden CJF, Guche laar H-J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30: 609-41.
80. Jakobisiak M, Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev 2010; 30: 102-35.
81. Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 2006; 5: 2706-15.
82. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006; 11: 306-15.
83. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-9.
84. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131: 1282-8.
85. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84: 886-91.